HR Execs on the Move

Concert Pharmaceuticals

www.concertpharma.com

 
Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel medicines designed to address unmet patient needs. The Company`s approach starts with previously studied compounds, including approved drugs, in which deuterium substitution has the potential to enhance clinical safety, tolerability or efficacy. Concert has a broad pipeline of innovative medicines targeting autoimmune and inflammatory diseases and central nervous systems (CNS) disorders.
  • Number of Employees: 100-250
  • Annual Revenue: $100-250 Million

Executives

Name Title Contact Details
Kimberly Mack
Senior Director Human Resources Profile

Similar Companies

Quality of Life Health Services

Quality of Life Health Services is a Gadsden, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

NovaBioMed Inc

NovaBioMed Inc is a Kentville, NS-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

PRA International

PRA International is a Raleigh, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bicara

Bicara Therapeutics is a clinical-stage company developing first-in-class biologics engineered to bring together the precision of targeted therapy and the power of tumor modulators. The company`s dual-action biologics are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, potentially offering long-lasting efficacy.

Ripple Therapeutics

The Ripple Therapeutics Epidel® technology is founded on a discovery that drugs can be engineered into controlled release materials without the use of polymers or excipients. The proprietary prodrugs are new chemical entities (NCEs) that have unique properties that allow them to be processed into standalone drug delivery implants (e.g. intravitreal implants, micro/nanoparticles, etc.) or as coatings on medical devices. Ripple Therapeutics implants and coatings are made up entirely from the prodrug without a polymeric carrier to control the implant or drug release properties. The implants and coatings undergo surface erosion to give zero order drug release profiles and are highly engineerable (e.g. different forms, shapes, and sizes) to tailor drug dose and duration for the specific indication of interest. The flexibility in molecular design results in drug doses that are within the therapeutic window, delivering the right amount of drug for the right amount of time. This has the potential to improve patient safety and clinical outcomes.